(Reuters) - The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for chikungunya, a virus transmitted by mosquitoes. The recommendations ...

Chikungunya is a mosquito-borne tropical disease that causes intense joint pain and fever. Although it is rare in the U.S., about 100 to 200 cases are reported annually, mostly among Americans ...

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) issued advisories late last week regarding the vaccine Ixchiq, developed by Valneva. Chikungunya is ...

Kennedy's move appears to shortcut the CDC's outside vaccine advisers, dropping COVID vaccines from the list recommended for ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths. About 80,000 Ixchiq doses ...

Due to an ongoing investigation of serious adverse events, it is recommended that the use of Ixchiq ® (chikungunya vaccine ... Disease Control and Prevention (CDC). According to the Agencies ...